Skin Autofluorescence, as a Measure of AGE Accumulation in Individuals Suffering from Chronic Plaque Psoriasis

Background Psoriasis is currently regarded as a chronic systemic inflammatory disease associated with increased cardiovascular risk. Advanced glycation end products (AGEs) contribute to the development of atherosclerosis. Objectives The aim of the study was the assessment of skin autofluorescence (SAF), as a measure of AGE accumulation, in individuals suffering from chronic plaque psoriasis without any comorbid conditions. Methods A study group consisted of 70 patients with chronic plaque psoriasis without any comorbid conditions and 59 healthy controls, matched by age and gender. AGE accumulation was assessed by SAF (AGE Reader, DiagnOptics BV) which is a validated and noninvasive technique. Relations between SAF and some clinical and laboratory data were assessed. Results SAF was positively correlated with age both in patients with psoriasis and controls (R = 0.722, p < 0.00001 and R = 0.613, p < 0.00001, respectively). There was significantly increased SAF in patients with psoriasis with elevated levels of C-reactive protein (CRP) and increased erythrocyte sedimentation rate (ESR) compared to controls (p < 0.00001; p < 0.00001, respectively, after adjustment to age). Increased SAF was found in psoriatic patients with prediabetes (HbA1c 5.7–6.4%) compared to controls (p < 0.0012, after adjustment to age). Conclusion Systemic inflammation (increased CRP level), prediabetes, and aging may influence enhanced AGE accumulation in patients with psoriasis without any comorbidities. SAF may be considered as a useful, noninvasive method to identify patients with psoriasis at increased cardiovascular risk.

[1]  Alan W. Stitt,et al.  Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs , 1997, Molecular medicine.

[2]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[3]  M. F. Weiss,et al.  Mechanisms for the formation of glycoxidation products in end-stage renal disease. , 2000, Kidney international.

[4]  Thomas de Quincey [C] , 2000, The Works of Thomas De Quincey, Vol. 1: Writings, 1799–1820.

[5]  J. Wautier,et al.  Advanced glycation end products, their receptors and diabetic angiopathy. , 2001, Diabetes & metabolism.

[6]  장윤희,et al.  Y. , 2003, Industrial and Labor Relations Terms.

[7]  R. de Caterina,et al.  Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.

[8]  A. Smit,et al.  The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. , 2004, Current medicinal chemistry.

[9]  Reindert Graaff,et al.  Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[10]  A. Smit,et al.  Simple Noninvasive Measurement of Skin Autofluorescence , 2005, Annals of the New York Academy of Sciences.

[11]  A. Smit,et al.  Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. , 2006, Rheumatology.

[12]  S. Fukumoto,et al.  Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. , 2008, Metabolism: clinical and experimental.

[13]  J. Meyerovitch,et al.  Psoriasis and diabetes: a population‐based cross‐sectional study , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  R. Graaff,et al.  Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. , 2008, Rheumatology.

[15]  Reindert Graaff,et al.  Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events , 2009, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[16]  A. Smit,et al.  AGE and their receptor RAGE in systemic autoimmune diseases: An inflammation propagating factor contributing to accelerated atherosclerosis , 2009, Autoimmunity.

[17]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[18]  A. Menter,et al.  Exploring the association between cardiovascular and other disease‐related risk factors in the psoriasis population: the need for increased understanding across the medical community , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  A. Smit,et al.  Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease , 2010, Current opinion in nephrology and hypertension.

[20]  A. Smit,et al.  Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease , 2011, Arthritis research & therapy.

[21]  H. Tse,et al.  Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation , 2011, The British journal of dermatology.

[22]  A. Covic,et al.  Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Non-invasive Technique - Skin Autofluorescence. , 2011, Maedica.

[23]  W. Boehncke,et al.  The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity , 2011, Experimental dermatology.

[24]  S. Yamagishi,et al.  Tissue level of advanced glycation end products is an independent determinant of high‐sensitivity C‐reactive protein levels in haemodialysis patients , 2011, Nephrology.

[25]  A. Smit,et al.  Dermal factors influencing measurement of skin autofluorescence. , 2011, Diabetes technology & therapeutics.

[26]  T. Wielkoszyński,et al.  Advanced protein glycation in psoriasis , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  G. Rutten,et al.  Advanced glycation end products measured by skin autofluorescence in a population with central obesity , 2012, Dermato-endocrinology.

[28]  A. Jenkins,et al.  Non‐invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non‐invasive measure of vascular dysfunction , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[29]  A. Smit,et al.  Skin Autofluorescence Based Decision Tree in Detection of Impaired Glucose Tolerance and Diabetes , 2013, PloS one.

[30]  S. Yamagishi Advanced Glycation End-Products , 2013 .

[31]  P. Barberger‐Gateau,et al.  Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. , 2013, Diabetes & metabolism.

[32]  P. Dagnelie,et al.  Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study , 2016, Hypertension.

[33]  Gorjan Alagic,et al.  #p , 2019, Quantum information & computation.

[34]  K. Khunti,et al.  Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations , 2017, Postgraduate Medical Journal.

[35]  M. Shin,et al.  Comparative study of skin autofluorescence expression in atopic dermatitis and psoriasis: A prospective in vivo study , 2017, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[36]  S. Magnusson,et al.  Skin autofluorescence is associated with arterial stiffness and insulin level in endurance runners and healthy controls - Effects of aging and endurance exercise , 2017, Experimental Gerontology.

[37]  E. Feskens,et al.  Advanced glycation end‐products (AGEs) and associations with cardio‐metabolic, lifestyle, and dietary factors in a general population: the NQplus study , 2017, Diabetes/metabolism research and reviews.

[38]  R. Sarpong,et al.  Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02572c , 2019, Chemical science.

[39]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[40]  Tsuyoshi Murata,et al.  {m , 1934, ACML.